Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial

Cabanillas Maria E.; de Souza Jonas A.; Geyer Susan; Wirth Lori J.; Menefee Michael E.; Liu Stephen V.; Shah Komal; Wright John; Shah Manisha H.

首页> 外文期刊>Journal of Clinical Oncology >Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial

【24h】

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial

机译：Cabozantinib作为酪氨酸激酶抑制剂抑制剂患者的救人疗法分化甲状腺癌：多中心II期国际甲状腺肿瘤学群试验的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2017年第29期|共9页
作者
Cabanillas Maria E.; de Souza Jonas A.; Geyer Susan; Wirth Lori J.; Menefee Michael E.; Liu Stephen V.; Shah Komal; Wright John; Shah Manisha H.;
展开▼
作者单位

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

Univ Chicago Med Ctr Chicago IL 60637 USA;

Univ S Florida Tampa FL USA;

Massachusetts Gen Hosp Boston MA 02114 USA;

Mayo Clin Jacksonville 4500 San Pablo Rd Jacksonville FL 32224 USA;

MedStar Georgetown Univ Hosp Washington DC USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

NCI Washington DC USA;

Ohio State Univ A438 Starling Loving Hall 320 W 10th Ave Columbus OH 43210 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial [J] . Cabanillas Maria E., de Souza Jonas A., Geyer Susan, Journal of Clinical Oncology . 2017,第29期

机译：Cabozantinib作为酪氨酸激酶抑制剂抑制剂患者的救人疗法分化甲状腺癌：多中心II期国际甲状腺肿瘤学群试验的结果
2. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第4期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
3. Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: A multicenter phase II trial of the Hellenic Oncology Research Group (HORG) [J] . KoinisF., PolyzosA., ChristopoulouA., Cancer chemotherapy and pharmacology. . 2014,第4期

机译：多西他赛和聚乙二醇化脂质体阿霉素对铂和紫杉烷敏感的卵巢癌患者的挽救性化疗：希腊肿瘤研究小组（HORG）的多中心II期临床试验
4. Clinical Engineering and Clinical Dosimetry in Patients with Differentiated Thyroid Cancer Undergoing Thyroid Remnant Ablation with Radioiodine-131 [C] . M. Medvedec, D. Dodig 12th Mediterranean conference on medical and biological engineering and computing 2010 . 2010

机译：放射性碘131消融甲状腺分化型甲状腺癌患者的临床工程和临床剂量
5. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial [O] . Maria E. Cabanillas, Jonas A. de Souza, Susan Geyer, -1

机译：卡博替尼作为酪氨酸激酶抑制剂-难治性分化型甲状腺癌患者的挽救疗法：多中心II期国际甲状腺肿瘤小组试验的结果
6. 421P A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China [O] . M. Gao, M. Ge, Z. Xu, 2020

机译：421P在中国患者（PTS）中的Lenvatinib（LEN）的多中心，随机，双盲，安慰剂（PbO） - 在中国患者（PTS）中的Lenvatinib（LEN）的III期试验

相关主题

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial

摘要

著录项

相似文献

相关主题

期刊订阅